-
dressNature Reviews Drug Discovery 08/2012; 11(8):597-8. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 02/2012; 11(2):103-4. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL).
dressNature Reviews Drug Discovery 01/2012; 11(1):19-20. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 01/2012; 11(5):349-50. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.
dressNature Reviews Drug Discovery 11/2011; 10(11):811-2. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 07/2011; 10(7):489-90. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 05/2011; 10(5):335-6. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 01/2011; 10(1):17-8. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test.
dressNature Reviews Drug Discovery 01/2011; 10(12):897-8. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody-drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL).
dressNature Reviews Drug Discovery 01/2011; 11(1):19-20. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In September 2010, pegloticase (Krystexxa; Savient Pharmaceuticals), a recombinant urate oxidase conjugated to polyethylene glycol (PEG), was approved by the US Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy.
dressNature Reviews Drug Discovery 12/2010; 10(1):17-18. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010.
dressNature Reviews Drug Discovery 11/2010; 9(11):837-8. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010.
dressNature Reviews Drug Discovery 10/2010; 9(11):837-838. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In July 2010, roflumilast (Daxas; Nycomed) was granted marketing authorization by the European Commission for the maintenance treatment of severe chronic obstructive pulmonary disease, as an add-on to bronchodilator treatment.
dressNature Reviews Drug Discovery 10/2010; 9(10):761-2. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In July 2010, roflumilast (Daxas; Nycomed) was granted marketing authorization by the European Commission for the maintenance treatment of severe chronic obstructive pulmonary disease, as an add-on to bronchodilator treatment.
dressNature Reviews Drug Discovery 09/2010; 9(10):761-762. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 08/2010; 9(8):591-2. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the European Commission for the treatment of postmenopausal women with osteoporosis who are at increased risk of fracture, and for the treatment of bone loss associated with hormone ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after, in June 2010, denosumab was approved by the US FDA for the treatment of postmenopausal women with osteoporosis at high risk of fracture.
dressNature Reviews Drug Discovery 07/2010; 9(8):591-592. · 29.01 Impact Factor
-
dressNature Reviews Drug Discovery 07/2010; 9(7):513-4. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.
dressNature Reviews Drug Discovery 06/2010; 9(7):513-514. · 29.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
dressNature Reviews Drug Discovery 05/2010; 9(5):357-8. · 29.01 Impact Factor
